【作者】 石卫峰； 归成； 李晓宇； 黄堃； 刘皋林；

【Author】 SHI Weifeng, GUI Cheng, LI Xiaoyu, LIU Gaolin (Department of Pharmacy, The First People’s Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200080, China) HUANG Kun (The Institute of Science and Technology Information, Shanghai Food and Drug Administration Bureau, Shanghai 200040, China)

【机构】 上海交通大学附属第一人民医院药剂部； 上海市食品药品监督管理局科技情报所；

【摘要】 目的:评价上海地区医院调脂药的应用现状及趋势。方法:采用回顾性方法,对上海地区119家医院2010-2012年临床应用的调脂药品种、销售金额、用药频度(DDDs)、日均费用(DDC)等进行统计和分析。结果:该地区医院2010-2012年调脂药的总销售金额逐年增长,且增速逐年扩大;他汀类药物占据调脂药市场的绝对主导地位,其后依次为中成药类和贝特类;2010-2011年销售金额排序列前3位的是阿托伐他汀、辛伐他汀和普伐他汀,2012年依次为阿托伐他汀、瑞舒伐他汀和辛伐他汀;2010-2011年DDDs排序前3位的是阿托伐他汀、辛伐他汀和非诺贝特,2012年依次为阿托伐他汀、辛伐他汀和瑞舒伐他汀。结论:高效、安全、依从性好的他汀类药物受到临床青睐,成为上海地区医院调脂药中的首选药物,今后市场前景继续看好。更多还原

【Abstract】 Objective: To evaluate the status quo and tendency of the utilization of lipid modifying agents (LMAs) in hospitals of Shanghai. Methods: By retrospective analysis, the utilization of LMAs in 119 sample hospitals of Shanghai area during the period of 2010-2012 was analyzed statistically in respect of categories of drugs, consumption sum, DDDs and DDC. Results: The consumption sum of LMAs increased year by year in Shanghai, with the growth rate going up. Statins occupied a absolute leading position in the market of LMAs,followed with Chinese patent medicines and fibrates. Atorvastatin, simvastatin and pravastatin ranked the top 3 in the list of consumption sum during 2010-2011 and atorvastatin ,rosuvastatin and simvastatin occupied the top 3 in 2012. Atorvastatin ,simvastatin and fenofibrate ranked the top 3 in the list of DDDs during 2010-2011 and atorvastatin , simvastatin and rosuvastatin occupied the top 3 in 2012. Conclusion: The application of OHAs in Shanghai area was rational basically. The OHAs with high efficiency, good safety and tolerability are welcomed in the clinic.更多还原